Three ileus cases associated with the use of dipeptidyl peptidase-4 inhibitors in diabetic patients.
Dipeptidyl peptidase (DPP)-4 inhibitors are a new class of antidiabetic drugs that increase incretin hormone levels to enhance blood sugar level-dependent insulinotropic effects, suppress glucagon action, and reduce bowel motility. These incretin effects are ideal for blood sugar control. However, the safety profile of DPP-4 inhibitors is not yet established. Herein, we present three cases of ileus, considered to be closely related to the use of DPP-4 inhibitors, in diabetic patients. Each of the three patients exhibited some risk of a deficiency in bowel movement; the onset of ileus was within 40 days after strengthened inhibition of DPP-4. The use of a DPP-4 inhibitor could be safe, although the cases presented herein enable us to inform the scientific community to some of the potential adverse effects of the use of DPP-4 inhibitors in select populations.
Department of Diabetology and Endocrinology Kanazawa Medical University Ishikawa Japan.
Keizo
K
Kanasaki
Department of Diabetology and Endocrinology Kanazawa Medical University Ishikawa Japan.
Kazunori
K
Konishi
Department of Gastroenterology Kanazawa Medical University Ishikawa Japan.
Ranji
R
Hayashi
Department of Gastroenterology Kanazawa Medical University Ishikawa Japan.
Hisakazu
H
Shiroeda
Department of Gastroenterology Kanazawa Medical University Ishikawa Japan.
Tomoe
T
Nomura
Department of Diabetology and Endocrinology Kanazawa Medical University Ishikawa Japan.
Atsushi
A
Nakagawa
Department of Diabetology and Endocrinology Kanazawa Medical University Ishikawa Japan.
Takako
T
Nagai
Department of Diabetology and Endocrinology Kanazawa Medical University Ishikawa Japan.
Ai
A
Takeda-Watanabe
Department of Diabetology and Endocrinology Kanazawa Medical University Ishikawa Japan.
Hiroki
H
Ito
Department of Diabetology and Endocrinology Kanazawa Medical University Ishikawa Japan.
Shin-Ichi
S
Tsuda
Department of Diabetology and Endocrinology Kanazawa Medical University Ishikawa Japan.
Munehiro
M
Kitada
Department of Diabetology and Endocrinology Kanazawa Medical University Ishikawa Japan.
Mizue
M
Fujii
Department of Diabetology and Endocrinology Kanazawa Medical University Ishikawa Japan.
Megumi
M
Kanasaki
Department of Diabetology and Endocrinology Kanazawa Medical University Ishikawa Japan.
Makoto
M
Nishizawa
Department of General and Digestive Surgery Kanazawa Medical University Ishikawa Japan.
Yasuharu
Y
Nakano
Department of General and Digestive Surgery Kanazawa Medical University Ishikawa Japan.
Yasuto
Y
Tomita
Department of General and Digestive Surgery Kanazawa Medical University Ishikawa Japan.
Nobuhiko
N
Ueda
Department of General and Digestive Surgery Kanazawa Medical University Ishikawa Japan.
Takeo
T
Kosaka
Department of Diabetology and Endocrinology Kanazawa Medical University Ishikawa Japan.
Daisuke
D
Koya
Adverse drug reaction; Complication; Dipeptidyl peptidase‐4; Niveau